Lodi

Researchers are studying children aged 0 to 2 years who have been hospitalized for bronchiolitis, a common lung infection. The study compares two different strategies designed to improve how doctors prescribe follow-up care that families can use as needed after hospital discharge. This is important because many automatic follow-up visits may not be necessary, and the study aims to reduce unnecessary visits while supporting families' preferences. The study tests two approaches: a moderate-resource strategy and a high-resource strategy. The moderate approach provides education for doctors and families, review of doctors' performance, and materials to help with clinical decisions. The high-resource strategy includes all these components plus additional small-group sessions and expert coaching to support doctors in follow-up care decisions. Participants will be monitored to see how well these strategies increase as-needed follow-up prescriptions within 7 days after leaving the hospital. Families and doctors will be supported with educational and decision-making materials. The study focuses on improving care after hospital discharge while minimizing unnecessary clinic visits, aiming for better, more personalized follow-up care for children with bronchiolitis.

Researchers are evaluating the Nevro1 Sacroiliac (SI) Transfixing and Fusion System to treat sacroiliac joint dysfunction in adults aged 21 and older. The study aims to find out what percentage of patients experience meaningful pain relief without adverse events, and how many achieve joint fusion at one and two years after treatment. This clinical study is observational and focuses on long-term outcomes following the use of this medical device. The Nevro1 device is a titanium cage implanted from the back of the sacroiliac joint. Anchors are deployed to stabilize the joint, and the device has openings that surgeons fill with the patient's own bone graft to encourage fusion. The study follows patients treated with this system as part of standard care, assessing the results over time without comparison to other treatments. Participants will be monitored through scheduled visits where researchers will assess pain relief and safety outcomes. The main outcome measured is a combination of pain relief and absence of adverse events at six months. The study also tracks fusion of the joint at one and two years. Patients must consent to participate and be able to follow study procedures throughout the observation period.